<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581879</url>
  </required_header>
  <id_info>
    <org_study_id>40350</org_study_id>
    <nct_id>NCT01581879</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions</brief_title>
  <official_title>Randomized, 2-way Crossover, Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg in Healthy Subjects Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of ziprasidone 20
      mg capsules versus Geodon 20 mg capsules under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, 2-way crossover, bioequivalence study of Ziprasidone 20 mg capsules and Geodon 20
      mg capsules in healthy subjects under fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>1, 2, 3, 3.50, 4, 4.50, 5, 5.50, 6, 6.50, 7, 8, 9, 10, 12, 16, 24 and 36 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ziprasidone HCL Capsules, 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Geodon Capsules, 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geodon Capsules, 20 mg of Pfizer Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone Hydrochloride</intervention_name>
    <description>Ziprasidone HCL Capsules, 20 mg</description>
    <arm_group_label>Ziprasidone HCL Capsules, 20 mg</arm_group_label>
    <arm_group_label>Geodon Capsules, 20 mg</arm_group_label>
    <other_name>Geodon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, smoker or non-smoker, 18 years of age and older.

          -  Capable of consent.

          -  BMI between 19.0 and 30.0 kg/m2 inclusively.

        Exclusion Criteria:

          -  Clinically significant illnesses within 4 weeks prior to the administration of the
             study medication.

          -  Clinically significant surgery within 4 weeks prior to the administration of the study
             medication.

          -  Any clinically significant abnormality found during medical screening.

          -  Any reason which, in the opinion of the Investigator, would prevent the subject from
             participating in the study.

          -  Abnormal laboratory tests judged clinically significant.

          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.

          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood
             pressure lower than 100 or over 140 mmHg, diastolic blood pressure lower than 60 or
             over 90 mmHg, or heart rate less than 60 or over 100 bpm) at screening.

          -  Qtc &gt; 430 for males and Qtc &gt; 450 for females.

          -  History of significant alcohol abuse or drug abuse within one year prior to the
             screening visit.

          -  Regular use of alcohol within six months prior to the screening visit ( more than
             fourteen units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL
             of 40% alcohol]).

          -  Use of soft drugs (such as marijuana) within 3 months prior to the screening visit or
             hard drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to the
             screening visit or positive urine drug screen at screening.

          -  History of allergic reaction to heparin, ziprasidone, or other related drugs.

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole;
             examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides,
             imidazole, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days
             prior to administration of the study medication.

          -  Use of an investigational drug or participation in an investigational study within 30
             days prior to administration of the study medication.

          -  Clinically significant history or presence of any clinically significant
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),
             unresolved gastrointestinal symptoms(e.g. diarrhea, vomiting), liver or kidney
             disease, or other conditions known to interfere with the absorption, distribution,
             metabolism, or excretion of the drug.

          -  Any clinically significant history or presence of clinically significant neurological
             endocrinal cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or
             metabolic disease.

          -  Use of prescription medication within 14 days prior to administration of study
             medication or over-the-counter products (including natural food supplements, vitamins,
             garlic as a supplement) within 7 days prior to administration of study medication,
             except for topical products without systemic absorption and hormonal contraceptives.

          -  Difficulty to swallow study medication.

          -  Smoking more than 25 cigarettes per day.

          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the
             Medical Sub-Investigator, could contraindicate the subject's participation in this
             study.

          -  A depot injection or an implant of any drug (other than hormonal contraceptives)
             within 3 months prior to administration of study medication.

          -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or
             loss of whole blood (excluding the volume of blood that will be drawn during the
             screening procedures of this study) prior to administration of the study medication as
             follows.

               1. 50 mL to 300 mL of whole blood within 30 days,

               2. 301 mL to 500 mL of whole blood within 45 days, or

               3. more than 500 mL of whole blood within 56 days prior to drug administration.

          -  Consumption of food or beverages containing grapefruit (e.g. fresh, canned, or frozen)
             within 7 days prior to administration of the study medication.

          -  History or known presence of tardive dyskinesia.

          -  History of neuroleptic malignant syndrome.

          -  History or known presence of clinically significant cardiac diseases (such as heart
             failure, QT prolongation, congenital long QT syndrome, myocardial infarction, cardiac
             arrhythmias, conduction abnormalities) or other conditions such as electrolyte
             disturbance, hypokalemia or hypomagnesemia.

          -  Breast-feeding subject.

          -  Positive urine pregnancy test at screening.

          -  Female subjects of childbearing potential having unprotected sexual intercourse with
             any non-steril male partner (i.e male who has not been sterilized by vasectomy for at
             least 6 months ) within 14 days prior to study drug administration. Acceptable methods
             of contraception.

               1. intra-uterine contraceptive device (placed at least 4 weeks prior to study drug
                  administration;

               2. condom or diaphragm + spermicide;

               3. hormonal contraceptives (starting at least 4 weeks prior to study drug
                  administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio R. Pizarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC Ft. Myers, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC Ft. Myers, Inc.</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>April 19, 2012</last_update_submitted>
  <last_update_submitted_qc>April 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Ziprasidone hydrochloride</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

